Agios Proof-of-Concept in Thalassemia Based on Preliminary Phase 2 Results

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients –

– Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency –

– Additional Data for the Phase 2 Study of Mitapivat in Thalassemia to be Presented at a Medical Meeting in the First Half of 2020 –

– Company to Host ASH Investor Event and Webcast Monday, December 9 at 8:00 p.m. ET –

https://www.marketscreener.com/AGIOS-PHARMACEUTICALS-IN-13709228/news/Agios-Establishes-Proof-of-Concept-for-Mitapivat-in-Non-transfusion-dependent-Thalassemia-Based-on-P-29698407/